RAPT Therapeutics, Inc.

    RAPT Therapeutics, Inc.

    NNASDAQ:RAPT
    - -
    USD
    - -
    - -
    RAPT Therapeutics, Inc.
    NASDAQ:RAPT
    (Nasdaq Stock Market)

    Recent

    price

    - -

    P/E

    ratio

    - -

    div

    yld

    - -

    ROIC.AI

    2017
    2018
    2019
    2020
    2021
    2022
    2023
    2024
    TTM
    USD
    - -
    - -
    - -
    1.67
    1.11
    0.38
    - -
    - -
    - -
    Revenue per Share
    -16.11
    -16.69
    -79.14
    -17.53
    -20.21
    -20.61
    -24.37
    -25.49
    -4.88
    Basic EPS, GAAP
    -15.63
    -16.83
    -66.93
    -13.55
    -18.04
    -17.61
    -20.49
    -16.37
    -4
    Free Cash Flow per Basic Share
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Dividend per Share
    -45.81
    -54.92
    -298.08
    -71.21
    -82.96
    -90.44
    -101.14
    -120.61
    -30.78
    Book Value per Share
    -34.52
    -44.83
    134.59
    34.53
    54.44
    60.27
    30.68
    37.27
    7.01
    Tangible Book Value per Share
    2
    2
    1
    3
    3
    4
    5
    5
    22
    Basic Weighted Avg Shares
    - -
    - -
    - -
    5
    4
    2
    - -
    - -
    - -
    Sales/Revenue/Turnover
    - -
    - -
    - -
    -1,055.41
    -1,815.08
    -5,618.53
    - -
    - -
    - -
    Operating Margin (%)
    1
    1
    1
    1
    1
    1
    1
    1
    1
    Depreciation Expense
    -29
    -36
    -43
    -53
    -69
    -84
    -117
    -130
    -106
    Net Income, GAAP
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Effective Tax Rate (%)
    - -
    - -
    - -
    -1,049.03
    -1,814.95
    -5,490.37
    - -
    - -
    - -
    Profit Margin (%)
    45
    60
    71
    104
    183
    238
    140
    187
    148
    Working Capital
    - -
    - -
    - -
    - -
    - -
    7
    4
    2
    - -
    LT Debt
    -62
    -97
    73
    104
    186
    245
    147
    190
    152
    Total Equity
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Return on Invested Capital (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Return on Capital (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Return on Common Equity (%)

    Capital Structure

    USD

    •

    in mil. unless spec.
    Mar'25
    Jun'25
    Sep'25
    ST Debt
    2
    2
    2
    LT Borrowings
    - -
    - -
    - -
    LT Finance Leases
    2
    1
    - -
    Preferred Equity and Hybrid Capital
    - -
    - -
    - -
    Shares Outstanding
    17
    17
    17
    Market Capitalization
    104
    129
    559

    Working Capital

    USD

    •

    in mil. unless spec.
    Mar'25
    Jun'25
    Sep'25
    Total Current Assets
    183
    173
    161
    Cash, Cash Equivalents & STI
    179
    169
    157
    Accounts Receivable, Net
    - -
    - -
    - -
    Inventories
    - -
    - -
    - -
    Total Current Liabilities
    9
    13
    13
    Payables & Accruals
    4
    7
    7
    ST Debt
    2
    2
    2
    Deferred Revenue
    - -
    - -
    - -

    Growth Rates

    USD

    •

    in mil. unless spec.

    (avg. rate of change)

    10 years
    5 years
    1 year
    Total Equity
    - -
    28.41%
    29.16%
    Free Cash Flow
    - -
    20.3%
    -15.03%
    Net Income, GAAP
    - -
    25.1%
    11.19%
    Sales/Revenue/Turnover
    - -
    - -
    - -
    Total Cash Common Dividend
    - -
    - -
    - -

    Quarterly Revenue

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2023
    - -
    - -
    - -
    - -
    - -
    2024
    - -
    - -
    - -
    - -
    - -
    2025
    - -
    - -
    - -
    - -
    - -

    Quarterly Earnings Per Share

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2023
    -6.12
    -5.28
    -6.54
    - -
    -24.37
    2024
    -6.32
    -5.69
    -3.79
    -9.12
    -25.49
    2025
    -0.64
    -0.65
    -0.65
    - -
    - -

    Quarterly Dividends Per Share

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2023
    - -
    - -
    - -
    - -
    - -
    2024
    - -
    - -
    - -
    - -
    - -
    2025
    - -
    - -
    - -
    - -
    - -
    Similar Companies
    Business

    Company News

    Company News APIChatGPT

    • fool.com

      This Biotech Was Quietly Bought Before a $58 Per Share Takeout

    • fool.com

      This Investor Built a $56 Million Position in RAPT Last Quarter. It Was Just Acquired for $58 Per Share

    • fool.com

      This Fund Bet $20 Million on RAPT Therapeutics as Stock Surges 500% This Past Year and Buyout Offer Emerges

    • globenewswire.com

      Halper Sadeh LLC is Investigating Whether RAPT, CTGO, TBN, FOLD are Obtaining Fair Deals for their Shareholders

    • defenseworld.net

      Contrasting Solid Biosciences (NASDAQ:SLDB) & Rapt Therapeutics (NASDAQ:RAPT)

    • prnewswire.com

      Are RAPT, ALGT, LSTA, AVO Obtaining Fair Deals for their Shareholders?

    • prnewswire.com

      Are RAPT, ALGT, LSTA, AVO Obtaining Fair Deals for their Shareholders?

    • prnewswire.com

      Halper Sadeh LLC is Investigating Whether NWE, DHIL, RAPT are Obtaining Fair Prices for its Shareholders

    • businesswire.com

      RAPT Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of RAPT Therapeutics, Inc. - RAPT

    • globenewswire.com

      Halper Sadeh LLC Reminds Shareholders of RAPT, PEN, CVGW, FONR of the Firm’s Investigations

    • globenewswire.com

      BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: RAPT Therapeutics, Inc. (Nasdaq – RAPT), Penumbra, Inc. (NYSE – PEN), Calavo Growers, Inc. (Nasdaq – CVGW), FONAR Corporation (Nasdaq - FONR)

    • defenseworld.net

      Rapt Therapeutics (NASDAQ:RAPT) Reaches New 52-Week High – Should You Buy?

    • prnewswire.com

      Halper Sadeh LLC Encourages PEN, RAPT, LSTA Shareholders to Contact the Firm to Discuss Their Rights

    • globenewswire.com

      Halper Sadeh LLC Encourages PEN and RAPT Shareholders to Contact the Firm to Discuss Their Rights

    • businesswire.com

      RAPT Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of RAPT Therapeutics, Inc. - RAPT

    • zacks.com

      GSK to Boost Respiratory & Immunology Pipeline With $2.2B RAPT Buyout

    • feeds.benzinga.com

      S&P 500 Records Worst Session Since October: Investor Sentiment Dips, Fear & Greed Index In 'Neutral' Zone

    • prnewswire.com

      Halper Sadeh LLC Encourages CVGW, RAPT, CFLT Shareholders to Contact the Firm to Discuss Their Rights

    • fool.com

      Why Rapt Therapeutics Stock Soared Today

    • globenewswire.com

      BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: RAPT Therapeutics, Inc. (Nasdaq – RAPT), Penumbra, Inc. (NYSE – PEN), Calavo Growers, Inc. (Nasdaq – CVGW), FONAR Corporation (Nasdaq - FONR)